Chaperone Technologies Inc.
This article was originally published in Start Up
Executive Summary
More than 70% of the bacteria that cause hospital-acquired infections are resistant to at least one of the broad-spectrum antibiotics most commonly used to treat them. By targeting peptides at a single vital intracellular structure found in all microbes, Chaperone Technologies hopes to solve the drug resistance problem for good.